Atria Wealth Solutions Inc. raised its position in Kenvue Inc. (NYSE:KVUE – Free Report) by 106.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,257 shares of the company’s stock after purchasing an additional 9,432 shares during the period. Atria Wealth Solutions Inc.’s holdings in Kenvue were worth $390,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC raised its stake in Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after purchasing an additional 3,075,019 shares during the period. State Street Corp lifted its stake in shares of Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after acquiring an additional 18,283,473 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC boosted its stake in Kenvue by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock valued at $1,029,810,000 after acquiring an additional 399,846 shares during the last quarter. Finally, Harris Associates L P lifted its position in shares of Kenvue by 7.5% during the third quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after purchasing an additional 2,186,114 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Analysts Set New Price Targets
Several brokerages recently issued reports on KVUE. Barclays reduced their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. UBS Group reduced their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Citigroup lowered their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $23.08.
Kenvue Stock Down 0.3 %
Shares of Kenvue stock opened at $23.15 on Friday. The company has a market cap of $44.24 billion, a P/E ratio of 43.67, a P/E/G ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $21.39 and a 200 day moving average price of $22.23.
Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.54%. Kenvue’s dividend payout ratio is currently 154.72%.
Kenvue Company Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
- Five stocks we like better than Kenvue
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- How to Calculate Return on Investment (ROI)
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- What Do S&P 500 Stocks Tell Investors About the Market?
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.